Belite Bio Inc ADR (BLTE NASDAQ) stock market data APIs
$63.9107
-1.02(-1.6%)
as of July 14, 2025
Try our APIs with
free plan!
Belite Bio Inc ADR Financial Data Overview
Price chart is built with
Anychart
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Prev. Close
63.9107
Open
62.894
High
64.5654
Low
62.7501
52 wk Range
43.7-86.53
Market Cap
2 069 M
Shares Outstanding
32 545 K
EPS
-0.27
Beta
-1.445
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Belite Bio Inc ADR data using free add-ons & libraries
Get Belite Bio Inc ADR Fundamental Data
Belite Bio Inc ADR Fundamental data includes:
- Net Revenue:
- EBITDA: -47 009 752
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-14
- EPS/Forecast: -0.37
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Belite Bio Inc ADR News
New
Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress
Investing.com - H.C. Wainwright has reiterated a Buy rating and $100.00 price target on Belite Bio, Inc, ADR (NASDAQ:BLTE), currently trading at $56.81 with a market cap of $1.85 billion, following th...
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
- 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, In...
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
Belite Bio, Inc - 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) --...
BLTE Crosses Below Key Moving Average Level
In trading on Friday, shares of Belite Bio Inc (Symbol: BLTE) crossed below their 200 day moving average of $60.53, changing hands as low as $59.66 per share. Belite Bio Inc shares are currently trad...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
